Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia

被引:99
|
作者
Lin, John K. [1 ,2 ]
Lerman, Benjamin J. [3 ]
Barnes, James I. [1 ,2 ]
Boursiquot, Brian C. [3 ]
Tan, Yuan Jin [3 ]
Robinson, Alex Q. L. [2 ]
Davis, Kara L. [3 ]
Owens, Douglas K. [1 ,2 ]
Goldhaber-Fiebert, Jeremy D. [2 ]
机构
[1] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
QUALITY-OF-LIFE; ECONOMIC-EVALUATION; TERM SURVIVORS; HEALTH; CHILDREN; TRANSPLANT; CLOFARABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; TISAGENLECLEUCEL;
D O I
10.1200/JCO.2018.79.0642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel was recently approved to treat relapsed or refractory pediatric acute lymphoblastic leukemia. With a one-time infusion cost of $475,000, tisagenlecleucel is currently the most expensive oncologic therapy. We aimed to determine whether tisagenlecleucel is cost effective compared with currently available treatments.MethodsMarkov modeling was used to evaluate tisagenlecleucel in pediatric relapsed or refractory acute lymphoblastic leukemia from a US health payer perspective over a lifetime horizon. The model was informed by recent multicenter, single-arm clinical trials. Tisagenlecleucel (under a range of plausible long-term effectiveness) was compared with blinatumomab, clofarabine combination therapy (clofarabine, etoposide, and cyclophosphamide), and clofarabine monotherapy. Scenario and probabilistic sensitivity analyses were used to explore uncertainty. Main outcomes were life-years, discounted lifetime costs, discounted quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (3% discount rate).ResultsWith an assumption of a 40% 5-year relapse-free survival rate, tisagenlecleucel increased life expectancies by 12.1 years and cost $61,000/QALY gained. However, at a 20% 5-year relapse-free survival rate, life-expectancies were more modest (3.8 years) and expensive ($151,000/QALY gained). At a 0% 5-year relapse-free survival rate and with use as a bridge to transplant, tisagenlecleucel increased life expectancies by 5.7 years and cost $184,000/QALY gained. Reduction of the price of tisagenlecleucel to $200,000 or $350,000 would allow it to meet a $100,000/QALY or $150,000/QALY willingness-to-pay threshold in all scenarios.ConclusionThe long-term effectiveness of tisagenlecleucel is a critical but uncertain determinant of its cost effectiveness. At its current price, tisagenlecleucel represents reasonable value if it can keep a substantial fraction of patients in remission without transplantation; however, if all patients ultimately require a transplantation to remain in remission, it will not be cost effective at generally accepted thresholds. Price reductions would favorably influence cost effectiveness even if long-term clinical outcomes are modest.
引用
收藏
页码:3192 / +
页数:12
相关论文
共 50 条
  • [31] Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia
    Fu, Zexin
    Zhou, Jinlei
    Chen, Rui
    Jin, Yihua
    Ni, Ting
    Qian, Lingbo
    Xiao, Chi
    [J]. ONCOLOGY LETTERS, 2020, 20 (04)
  • [32] What Can Cost-Effectiveness Analysis Tell Us About Chimeric Antigen Receptor T-Cell Therapy for Relapsed Acute Lymphoblastic Leukemia?
    Flowers, Christopher R.
    Ramsey, Scott D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (32) : 3183 - +
  • [33] Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia
    Myers, Regina M.
    Fitzgerald, Julie
    Elgarten, Caitlin W.
    Getz, Kelly D.
    Li, Yimei
    Hogan, Jonathan
    Dinofia, Amanda
    Burrows, Evanette K.
    Aplenc, Richard
    Grupp, Stephan A.
    Laskin, Benjamin
    Maude, Shannon L.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [34] Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma
    Potnis, Kunal C.
    Di, Mengyang
    Isu, Iris
    Gowda, Lohith
    Seropian, Stuart E.
    Foss, Francine M.
    Forman, Howard P.
    Huntington, Scott F.
    [J]. BLOOD ADVANCES, 2023, 7 (05) : 801 - 810
  • [35] Potential Impact of Treatment with Inotuzumab Ozogamicin on Chimeric Antigen Receptor T-Cell Therapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Ceolin, Valeria
    Brivio, Erica
    Rheingold, Susan R.
    Leahy, Allison Barz
    Vormoor, Britta Julia
    O'Brien, Maureen M.
    Rubinstein, Jeremy
    Kalwak, Krzysztof
    De Moerloose, Barbara
    Jacoby, Elad
    Bader, Peter
    Fuster, Jose L.
    Locatelli, Franco
    Hoogerbrugge, Peter
    Calkoen, Friso
    Zwaan, Christian M.
    [J]. BLOOD, 2021, 138 : 3824 - +
  • [36] Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
    Ceolin, Valeria
    Brivio, Erica
    van Tinteren, Harm
    Rheingold, Susan R.
    Leahy, Allison
    Vormoor, Britta
    O'Brien, Maureen M.
    Rubinstein, Jeremy D.
    Kalwak, Krzysztof
    De Moerloose, Barbara
    Jacoby, Elad
    Bader, Peter
    Lopez-Duarte, Monica
    Goemans, Bianca F.
    Locatelli, Franco
    Hoogerbrugge, Peter
    Calkoen, Friso G.
    Zwaan, Christian Michel
    [J]. LEUKEMIA, 2023, 37 (01) : 53 - 60
  • [37] Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia
    Valeria Ceolin
    Erica Brivio
    Harm van Tinteren
    Susan R. Rheingold
    Allison Leahy
    Britta Vormoor
    Maureen M. O’Brien
    Jeremy D. Rubinstein
    Krzysztof Kalwak
    Barbara De Moerloose
    Elad Jacoby
    Peter Bader
    Mónica López-Duarte
    Bianca F. Goemans
    Franco Locatelli
    Peter Hoogerbrugge
    Friso G. Calkoen
    Christian Michel Zwaan
    [J]. Leukemia, 2023, 37 : 53 - 60
  • [38] CAR T-Cell Therapy Pediatric patients with relapsed and refractory acute lymphoblastic leukemia
    Callahan, Colleen
    Baniewicz, Diane
    Ely, Beth
    [J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2017, 21 (02) : 22 - 28
  • [39] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
    Ernst, Moritz
    Oeser, Annika
    Besiroglu, Burcu
    Caro-Valenzuela, Julia
    Aziz, Mohamed Abd El
    Monsef, Ina
    Borchmann, Peter
    Estcourt, Lise J.
    Skoetz, Nicole
    Goldkuhle, Marius
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
  • [40] Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
    Zhu, Feng
    Wei, Guoqing
    Zhang, Mingming
    Zhao, Houli
    Wu, Wenjun
    Yang, Luxin
    Hu, Yongxian
    Huang, He
    [J]. CELL TRANSPLANTATION, 2020, 29